Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe.
J Exp Clin Cancer Res
; 43(1): 159, 2024 Jun 06.
Article
in En
| MEDLINE
| ID: mdl-38840237
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Xenograft Model Antitumor Assays
/
DNA Repair
/
TOR Serine-Threonine Kinases
/
Survivin
/
Kidney Neoplasms
Limits:
Animals
/
Humans
Language:
En
Journal:
J Exp Clin Cancer Res
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: